<DOC>
	<DOC>NCT00735332</DOC>
	<brief_summary>The objective of this study is to assess the efficacy and safety of TLN-232 used to treat patients with metastatic melanoma that recur/progress after receiving first line systemic therapy.</brief_summary>
	<brief_title>Efficacy Study of TLN-232 in Patients With Recurring Metastatic Melanoma</brief_title>
	<detailed_description />
	<mesh_term>Melanoma</mesh_term>
	<criteria>Histologically confirmed stage IV (M1a, M1b, and M1c) unresectable metastatic melanoma (cutaneous, mucosal or acral lentiginous) First progression after treatment by one first line systemic therapy for metastatic melanoma (immunotherapy or targeted therapy or chemotherapy or any combination of them) Measurable recurrent/progressive disease by radiological scan ≤ 21 days prior to Day 1, Cycle 1 Age ≥ 18 years ECOG ≤ 2 Normal organ and marrow function as defined below: Leukocytes ≥2.5 x 109/L Absolute neutrophil count ≥1.5 x 109/L Platelets ≥100 x 109/L Hemoglobin ≥100 g/L (10g/dL) Total bilirubin ≤1.5 X institutional ULN AST(SGOT)/ALT(SGPT) ≤2.5 X institutional ULN Creatinine ≤1.5 X institutional ULN Patients with a life expectancy ≤ 16 weeks Patients with ocular melanoma Patients with symptomatic and/or unstable brain metastasis during the last 3 months (90 days) prior to Day 1, Cycle 1 Patients with a history of allergic reactions or hypersensitivity to somatostatin analogues Patients with a documented history of HIV, active hepatitis B or C infection Female patients who are pregnant or lactating Patients who are receiving hormonal therapy (with the exception of hormone replacement therapy and hormonal contraceptives), systemic steroids, immunosuppressive therapy or coumadin (low molecular weight heparin is permitted) Patients with grade ≥2 peripheral neuropathy (CTCAE criteria) Patients in whom a proper central line cannot be established</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2010</verification_date>
	<keyword>Melanoma</keyword>
	<keyword>Metastatic Melanoma</keyword>
	<keyword>Phase II</keyword>
	<keyword>Skin Cancer</keyword>
</DOC>